Category Archives: Biotechnology

Is stories

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... StockNewsUnion Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) continues to power high in the market on the back of a recently announced product distribution deal. A deal with Xenetic Biosciences is expected to make the company's products available on the ... Traders are Following Technical Levels for Prana Biotechnology Ltd (PRAN)Rives Journal Notable Institutional Stake In These Stocks: Prana Biotechnology (NASDAQ:PRAN), Adamis Pharmaceuticals ...Wallstreet Investorplace Does Prana Biotechnology Limited (PRAN)'s current closing price competes the market?TopChronicle WsNews 4investors -Is stories -Daily News Journal all 13 news articles »

See the rest here:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... - StockNewsUnion

Stocks Gallery

379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... The Cerbat Gem Emerald Advisers Inc. PA bought a new stake in shares of Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent Form 13F ... Puma Biotechnology (PBYI) Receives Daily Media Sentiment Rating of 0.44Sports Perspectives Credit Suisse Group AG Reaffirms "Outperform" Rating for Puma Biotechnology Inc (PBYI)Transcript Daily Puma Biotechnology, Inc.'s (PBYI) is at $40.55 per share and Abaxis, Inc.'s (ABAX) is listed at $45.84Stocks Gallery USA Commerce Daily -BBNS -HugoPress all 19 news articles »

See more here:
379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... - The Cerbat Gem

Advances in science, many of them from scientists at USDA or through research funded by USDA, have opened up new options for farmers responding to market needs and environmental challenges. Many new plant varieties being developed or grown by farmers have been produced using genetic engineering, which involves manipulating the plant's genes through techniques of modern molecular biology often referred to as recombinant DNA technology. These techniques are included in what is often referred to as "biotechnology" or "modern biotechnology."

USDA supports the safe and appropriate use of science and technology, including biotechnology, to help meet agricultural challenges and consumer needs of the 21st century. USDA plays a key role in assuring that biotechnology plants and products derived from these plants are safe to be grown and used in the United States. Once these plants and products enter commerce, USDA supports bringing these and other products to the worldwide marketplace.

Three federal agencies are involved in ensuring that plants produced using biotechnology and the many products derived from them are safe for farmers to use, safe to consume as food or feed, and safe for the environment. These are USDA's Animal and Plant Health Inspection Service, the Department of Health and Human Services' Food and Drug Administration, and the United States Environmental Protection Agency. The three agencies regulate these products based on the characteristics of the actual products and their intended uses, and they operate under the existing laws passed by Congress to ensure the safety of plants used in agriculture, the safety of pesticides used in agriculture, and the safety of foods we eat and feeds given to animals. Many other USDA agencies have roles in the development, use, and marketing of these products as well.

Learn more about How the U.S. Government Regulates Biotech Plants.

Since the first successful commercialization of a biotechnology-derived crop in the 1990s, many new crop varieties have been developed and made available to U.S. farmers and farmers worldwide. U.S. farmers have rapidly adopted many of these new GE varieties, so that in 2012, 88 percent of the corn, 94 percent of the cotton, and 93 percent of the soybeans planted in the U.S. were varieties produced through genetic engineering. A large proportion of the production of other crops, such as alfalfa, and papaya, and sugar beet, is also biotech-derived.

Read more about the reasons behind this trend and about how farming practices and the marketplace have changed on USDA's Economic Research Service Biotechnology page.

The United States is the largest exporter of agricultural products, which helps feed the world's population, and our export markets are critical to the health of U.S. farm communities around the country. Most of the corn and soybeans we export are biotechnology-derived, and this means that working with our trading partners is critical to help them understand the technical aspects of new products and how we have determined that they meet our high safety standards, to open up new markets, and to ensure that our products are treated fairly in the global marketplace.

The increasing use of biotechnology in agriculture has changed, and will continue to change, farming and the work of USDA in the long-term. To help understand and address these changes, USDA established the Advisory Committee on Biotechnology and 21st Century Agriculture (AC21). One critical area where the committee has focused its attention is how farmers who produce different crops intended for different customers-biotechnology-derived, conventional, or organic-can best co-exist and produce the crops that meet their customers' needs. The AC21 has provided a report to USDA, with recommendations, on this subject.

Visit the AC21 page to learn more.

Here is the original post:
Biotechnology | USDA

The USA Commerce

Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of ... The Cerbat Gem Puma Biotechnology logo Equities analysts expect that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings per share (EPS) of ($2.08) for the current ... Focusing the Lens on Puma Biotechnology, Inc. (NASDAQ:PBYI ...Rives Journal Stock Jumping Abnormally High: Puma Biotechnology, Inc. (PBYI)HugoPress Brokerage Firm Analysts Consensus on Puma Biotechnology, Inc ...Midway Monitor Concord Register -The USA Commerce all 8 news articles »

More here:
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of ... - The Cerbat Gem

By Isabella Zhong

Shenyang-based 3SBio (1530.HK) is a biopharmaceutical pioneer that offers a unique play on Chinas rising demand for healthcare.

The company is best known for its rheumatoid arthritis drug YSP, which accounts for 33% of revenues, and TPIAO, a hormone used in the treatment of platelet deficiencies.

While YSP and TPIAO are expected to deliver strong sales growth in coming years, a recent price cut for anemia drug EPIAO and limited R&D upside in the near term could weigh on 3SBio. Jefferies analyst Eugene Huang initiated coverage of the stock today with a hold rating and an HKD11.50 a share target price, which implies 11% upside.

Huang has more on 3SBios drugs pipeline:

3SBios HER2 (breast cancer) and CD20 (lymphoma) candidates were withdrawn, leaving peers like Fosun potentially to become FTM generics. Besides, we factored in Rmb20/50/110m 17/18/19E sales from Bydureon (exenatide ER, GLP-1, diabetes), which is pending NDA approval. We are concerned there might be a lack of synergy between 3SBio and AstraZenecas diabetes team as well as integration risks.

Shares of 3SBio are up 37% this year and trade at 23 times forward earnings, which is in line with its five year average. Analysts surveyed by FactSet expect 3SBio to grow earnings at a 28.3% average annual pace over the next three to five years. While the stocks scarcity value and long-term growth potential look appealing, investors may want to wait for a better entry point.

Continued here:
3SBio: Is this Chinese Biotechnology Stock a Buy? - Barron's (blog)

FinSMEs (blog)

Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M FinSMEs (blog) Paris, France based Advent France Biotechnology has held the first close of Advent France Biotechnology Seed-Fund I, at 64.75m (USD68.5m). Supported in by the National Seed-Fund (Fonds National d'Amorage) managed by Bpifrance under the ...

More here:
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M - FinSMEs (blog)

LONDON, UNITED KINGDOM--(Marketwired - Apr 28, 2017) - Planda Biotechnology, Inc. ( OTC PINK : PLPL ) ("Planda" or "the Company"), producer of the highly bioavailable Phytofare catechin complex, today announced that Ezra Jones has been appointed Vice President of Sales and Marketing, a role he assumes from Callum Cottrell-Duffield, who was recently named Chief Operating Officer of Planda.

Mr. Jones has been involved in sales of nutraceutical branded ingredients for the past 18 years. He was he was with NutraGenesis for 3.5 years, and has recently, before Planda, been working as an independent sales representative for numerous worldwide companies.Since 2016, Mr. Jones has overseen all North American sales efforts for Planda.As the new head of sales and marketing, his responsibilities will expand to overseeing all global sales efforts, working with the company's independent sales reps and distributors, building additional sales channels, and growing the Phytofare brand.

Callum Cottrell-Duffield, President of Planda, commented, "Having worked with Ezra for the past year, I have been impressed with his passion for the product and knowledge of the industry.He has been instrumental in opening our largest accounts and is a driven salesman.As we now expand into a global brand and introduce new products in the coming year, Ezra's experience in building and training a sales force will be invaluable."

About Planda Biotechnology, Inc.

Planda Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Planda Biotechnology controls every aspect of the process, from growing green tea on its farms in South Africa, to producing its proprietary Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Here is the original post:
Plandai Biotechnology Names Ezra Jones as Vice President of ... - Yahoo Finance

Needle moving action has been spotted in Cellect Biotechnology Ltd (APOPW) as shares are moving today onvolatility12.61% or $0.29 from the open.TheNASDAQ listed companysaw a recent bid of2.59 and49481shares have traded hands in the session.

Now letstake a look at how the fundamentals are stacking up for Cellect Biotechnology Ltd (APOPW). Fundamental analysis takes into consideration market, industry and stock conditions to help determine if the shares are correctly valued. Cellect Biotechnology Ltd currently has a yearly EPS of -0.14. This number is derived from the total net income divided by shares outstanding. In other words, EPS reveals how profitable a company is on a share owner basis.

Another key indicator that can help investors determine if a stock might be a quality investment is the Return on Equity or ROE. Cellect Biotechnology Ltd (APOPW) currently has Return on Equity of -86.72. ROE is a ratio that measures profits generated from the investments received from shareholders. In other words, the ratio reveals how effective the firm is at turning shareholder investment into company profits. A company with high ROE typically reflects well on management and how well a company is run at a high level. A firm with a lower ROE might encourage potential investors to dig further to see why profits arent being generated from shareholder money.

Another ratio we can look at is the Return on Invested Capital or more commonly referred to as ROIC. Cellect Biotechnology Ltd (APOPW) has a current ROIC of -86.72. ROIC is calculated by dividing Net Income Dividends by Total Capital Invested.

Similar to ROE, ROIC measures how effectively company management is using invested capital to generate company income. A high ROIC number typically reflects positively on company management while a low number typically reflects the opposite.

Turning to Return on Assets or ROA, Cellect Biotechnology Ltd (APOPW) has a current ROA of -74.92. This is a profitability ratio that measures net income generated from total company assets during a given period. This ratio reveals how quick a company can turn its assets into profits. In other words, the ratio provides insight into the profitability of a firms assets. The ratio is calculated by dividing total net income by the average total assets. A higher ROA compared to peers in the same industry, would suggest that company management is able to effectively generate profits from their assets. Similar to the other ratios, a lower number might raise red flags about managements ability when compared to other companies in a similar sector.

By

More:
Unusual Activity Spotted in Cellect Biotechnology Ltd (APOPW) - Rockville Register

Staff Reporter

Islamabad

Minister for National Food Security and Research Sikandar Hayat Khan Bosan called for establishing Islamic biotechnology center in order to develop the agriculture and related sectors for the socio-economic prosperity of Muslim countries. Addressing the 3rd International Conference on Agriculture, Food Security and Biotechnology on an other day, he said that government believes that practical collaboration among the Muslim countries in the cutting edge areas of modern biotechnology was the need of time. The event was organized by Pakistan Agricultural Research Council (PARC) in collaboration with COMSATS, Islamic Educational, Scientific and Cultural Organization (ISESCO) and CIMMYT. The aim of the conference was to share the international best practices of using the biotechnology for the development of agriculture sector and food security. The minister termed the exchange of eminent scientist for short term and graduating students among Islamic countries as another good form of cooperation. He called upon the scientists for encouraging and promoting smart agricultural practices to build the resilience in agri-sector. Pakistan was working on the development of infrastructure for using modern and innovative technologies including the biotechnology for uplift of agriculture, health and industrial sectors of the country, he added. Pakistan has improved its crop yield and productivity over the years and it was producing surplus of wheat, maize, potato and sugarcane, he added. He said that scientist and biotechnologist in Pakistan has achieved the diversification in seed development and moved to a higher value added seeds, particularly in the crops sector. The minister said that all the modern techniques should be replicated after tailor-made alterations keeping in view of local settings and environmental factors.

The rest is here:
Bosan for establishing Islamic Biotechnology Centre - Pakistan Observer

iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at Vetr Inc. The Cerbat Gem iShares NASDAQ Biotechnology Index logo Vetr upgraded shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) from a hold rating to a buy rating in a research note issued to investors on Wednesday. They currently have $301.57 price target on ... iShares NASDAQ Biotechnology Index (IBB) Stake Raised by Mycio Wealth Partners LLCSports Perspectives iShares NASDAQ Biotechnology Index (IBB) Position Lowered by Bartlett & Co. LLCBBNS The Crestwood Advisors Group LLC Acquires 5651 Shares of iShares NASDAQ Biotechnology Index (IBB)Petro Global News 24 all 6 news articles »

See the article here:
iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at Vetr Inc. - The Cerbat Gem